Ferreira, Joaquim J., Rosser, Anne Elizabeth ORCID: https://orcid.org/0000-0002-4716-4753, Craufurd, David, Squitieri, Ferdinando, Mallard, Nicholas and Landwehrmeyer, Bernhard 2015. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders 30 (10) , pp. 1426-1429. 10.1002/mds.26308 |
Abstract
BACKGROUND: It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45. METHODS: This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects of ethyl-EPA versus placebo on 290 subjects with mild-to-moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI). RESULTS: No significant differences in TMS-4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores. CONCLUSION: Ethyl-EPA was not beneficial in patients with HD during 6 months of placebo-controlled evaluation. © 2015 International Parkinson and Movement Disorder Society.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Biosciences Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Neuroscience and Mental Health Research Institute (NMHRI) |
Subjects: | R Medicine > R Medicine (General) |
Additional Information: | First published online 14 July 2015 |
Publisher: | John Wiley & Sons |
ISSN: | 0885-3185 |
Date of Acceptance: | 22 May 2015 |
Last Modified: | 28 Oct 2022 10:12 |
URI: | https://orca.cardiff.ac.uk/id/eprint/77149 |
Citation Data
Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |